RENB: Renovaro Inc. Stock

by  •  • Comments Off on RENB: Renovaro Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 211.19
Enterprise Value ($M) 218.13
Book Value ($M) 43.60
Book Value / Share 0.30
Price / Book 4.84
NCAV ($M) -12.02
NCAV / Share -0.08
Price / NCAV -17.57

Profitability (mra)
Return on Invested Capital (ROIC) -0.80
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.62

Liquidity (mrq)
Quick Ratio 0.17
Current Ratio 0.17

Balance Sheet (mrq) ($M)
Current Assets 2.40
Assets 58.02
Liabilities 14.42
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-08 13D/A William Anderson Wittekind 13.10 0.00
02-22 13G/A Abildgaard Ole 7.60 9.84
02-16 13D/A Sindlev Rene 10.28 35.49

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2023-11-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-10-30 10-K/A United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION report under sec
2023-10-02 10-K United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION report under section 13 Or 15(d) o

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 68,473 46,690 146.65
2024-05-01 35,594 123,714 28.77
2024-04-30 180,420 239,504 75.33
2024-04-29 53,329 115,969 45.99

(click for more detail)

Similar Companies
PULM – Pulmatrix, Inc. QLGN – Qualigen Therapeutics, Inc.
QLI – Qilian International Holding Group Limited REVB – Revelation Biosciences, Inc.
RGC – Regencell Bioscience Holdings Limited


Financial data and stock pages provided by
Fintel.io